STOCK TITAN

Biomea Fusion Inc - BMEA STOCK NEWS

Welcome to our dedicated news page for Biomea Fusion (Ticker: BMEA), a resource for investors and traders seeking the latest updates and insights on Biomea Fusion.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Biomea Fusion's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Biomea Fusion's position in the market.

Rhea-AI Summary
Biomea Fusion has received FDA and Health Canada clearance for the expansion portion of the COVALENT-111 Phase II study, evaluating BMF-219 in type 2 diabetes patients. 84% of patients dosed with BMF-219 in the escalation portion showed a reduction in HbA1c at Week 4 and 74% at Week 12. Topline results expected in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.24%
Tags
-
Rhea-AI Summary
Biomea Fusion appoints Juan Pablo Frías, M.D. as Chief Medical Officer to oversee clinical development of BMF-219 in type 2 and type 1 diabetes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.87%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.7%
Tags
Rhea-AI Summary
Biomea Fusion, Inc. has announced preliminary topline data from its Phase I clinical trial, COVALENT-101, showing initial responses in relapsed/refractory AML patients with menin-dependent mutations. Two complete responses were observed in five patients treated at Dose Level 4. The safety profile of BMF-219 supports further dose escalation, and enrollment for Dose Level 5 has begun. The company plans to present additional clinical data at an upcoming conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.58%
Tags
none
-
Rhea-AI Summary
Biomea Fusion, Inc. announces positive clinical data from its Phase II study of BMF-219 in patients with type 2 diabetes. The data shows improved beta cell function and glycemic control even after treatment cessation. The company plans to explore longer treatment durations and potential utility in type 1 diabetes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.52%
Tags
conferences clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.76%
Tags
none
-
Rhea-AI Summary
Biomea Fusion has received FDA clearance to begin a Phase I trial of its investigational covalent FLT3 inhibitor, BMF-500, in adult patients with relapsed or refractory acute leukemia. BMF-500 has shown high potency and selectivity in preclinical studies, and the company plans to explore its potential in combination with other targeted agents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.6%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.2%
Tags
conferences
Biomea Fusion Inc

Nasdaq:BMEA

BMEA Rankings

BMEA Stock Data

428.88M
19.38M
25.18%
87.06%
36.88%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Redwood City

About BMEA

biomea fusion, llc was formed in 2017 by a small group of biotech executives. we are dedicated to developing innovative medicines for patients. it is our goal to design and clinically develop patient friendly therapies with higher efficacy than the current standard of care. the more precise a therapeutic agent is, the better the potential outcomes for individual patients’ needs. we are a precision oncology company developing novel small molecules that target aggressive forms of cancer. patients with these aggressive tumors typically exhibit high mortality rates and suffer from inadequate treatment options. with our current program, we are targeting specific changes to the dna of patients, which can be isolated as key drivers for tumor growth. we leverage our internal expertise and compliment it with computational drug design technology to build novel medicines for the future. we have significantly invested in the upfront development of our targeted therapies and are conducting bro